The Role of Targeted Therapy in the Multi-Disciplinary Approach to Colorectal Liver Metastasis
Colorectal cancer (CRC) is the second most common cause of cancer-related mortality in the United States. Among newly diagnosed patients with CRC, 20% will present with metastatic disease and another 25% will develop metastases. The surgical resection of the primary tumor and metastatic disease site...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/13/3513 |
| _version_ | 1797591985075257344 |
|---|---|
| author | Samantha M. Ruff Alexander H. Shannon Timothy M. Pawlik |
| author_facet | Samantha M. Ruff Alexander H. Shannon Timothy M. Pawlik |
| author_sort | Samantha M. Ruff |
| collection | DOAJ |
| description | Colorectal cancer (CRC) is the second most common cause of cancer-related mortality in the United States. Among newly diagnosed patients with CRC, 20% will present with metastatic disease and another 25% will develop metastases. The surgical resection of the primary tumor and metastatic disease sites confers the best chance at long-term survival. Unfortunately, many patients will recur after resection or present with unresectable disease. As such, metastatic CRC is commonly treated with a combination of surgery, systemic therapy, and/or liver-directed therapies. Despite best efforts, 5-year survival for unresectable metastatic CRC is only about 20%. CRC is a heterogeneous disease and the underlying genetic differences inform behavior, treatment strategy, and prognosis. Given the limitations of cytotoxic chemotherapy and the growing role of molecular profiling, research has focused on identifying and developing targeted therapies. We herein review how genetic profiling informs prognosis, crucial cell-signaling pathways that play a role in CRC carcinogenesis, and currently approved targeted therapies for metastatic CRC. |
| first_indexed | 2024-03-11T01:45:23Z |
| format | Article |
| id | doaj.art-ab4a305dc09048d3a3ec2b24777b52c7 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T01:45:23Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-ab4a305dc09048d3a3ec2b24777b52c72023-11-18T16:18:06ZengMDPI AGCancers2072-66942023-07-011513351310.3390/cancers15133513The Role of Targeted Therapy in the Multi-Disciplinary Approach to Colorectal Liver MetastasisSamantha M. Ruff0Alexander H. Shannon1Timothy M. Pawlik2Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH 43210, USADepartment of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH 43210, USADepartment of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH 43210, USAColorectal cancer (CRC) is the second most common cause of cancer-related mortality in the United States. Among newly diagnosed patients with CRC, 20% will present with metastatic disease and another 25% will develop metastases. The surgical resection of the primary tumor and metastatic disease sites confers the best chance at long-term survival. Unfortunately, many patients will recur after resection or present with unresectable disease. As such, metastatic CRC is commonly treated with a combination of surgery, systemic therapy, and/or liver-directed therapies. Despite best efforts, 5-year survival for unresectable metastatic CRC is only about 20%. CRC is a heterogeneous disease and the underlying genetic differences inform behavior, treatment strategy, and prognosis. Given the limitations of cytotoxic chemotherapy and the growing role of molecular profiling, research has focused on identifying and developing targeted therapies. We herein review how genetic profiling informs prognosis, crucial cell-signaling pathways that play a role in CRC carcinogenesis, and currently approved targeted therapies for metastatic CRC.https://www.mdpi.com/2072-6694/15/13/3513colorectal cancermetastasestargeted therapyliver |
| spellingShingle | Samantha M. Ruff Alexander H. Shannon Timothy M. Pawlik The Role of Targeted Therapy in the Multi-Disciplinary Approach to Colorectal Liver Metastasis Cancers colorectal cancer metastases targeted therapy liver |
| title | The Role of Targeted Therapy in the Multi-Disciplinary Approach to Colorectal Liver Metastasis |
| title_full | The Role of Targeted Therapy in the Multi-Disciplinary Approach to Colorectal Liver Metastasis |
| title_fullStr | The Role of Targeted Therapy in the Multi-Disciplinary Approach to Colorectal Liver Metastasis |
| title_full_unstemmed | The Role of Targeted Therapy in the Multi-Disciplinary Approach to Colorectal Liver Metastasis |
| title_short | The Role of Targeted Therapy in the Multi-Disciplinary Approach to Colorectal Liver Metastasis |
| title_sort | role of targeted therapy in the multi disciplinary approach to colorectal liver metastasis |
| topic | colorectal cancer metastases targeted therapy liver |
| url | https://www.mdpi.com/2072-6694/15/13/3513 |
| work_keys_str_mv | AT samanthamruff theroleoftargetedtherapyinthemultidisciplinaryapproachtocolorectallivermetastasis AT alexanderhshannon theroleoftargetedtherapyinthemultidisciplinaryapproachtocolorectallivermetastasis AT timothympawlik theroleoftargetedtherapyinthemultidisciplinaryapproachtocolorectallivermetastasis AT samanthamruff roleoftargetedtherapyinthemultidisciplinaryapproachtocolorectallivermetastasis AT alexanderhshannon roleoftargetedtherapyinthemultidisciplinaryapproachtocolorectallivermetastasis AT timothympawlik roleoftargetedtherapyinthemultidisciplinaryapproachtocolorectallivermetastasis |